Introduction
Opioid use disorder (OUD) is an acute and growing public health problem. In 2013, OUD caused about 50 000 deaths worldwide and accounted for more than 40% of all sub stance abuse-related deaths. 1 Opioid use disorder is par ticularly prevalent in the United States, where the number of fatalities involving opioid overdose more than quadru pled from 5990 in 1999 to 29 467 in 2014, 2 despite the greater variety and availability of treatment options. These statistics suggest that urgent action is needed to increase the effec tiveness of the available OUD treatments.
Opioid use disorder is driven by the strongly reinforcing nature of opioid agonists, mediated predominantly by the μopioid receptor (MOR). 3 A major mechanism of MOR mediated reinforcement is inhibition of the GABAergic input into the ventral tegmental area (VTA), leading to dopamine re lease in the nucleus accumbens (NAcc). [4] [5] [6] Naltrexone (NTX) is a nonselective opioid antagonist that competitively blocks the effects of opioid agonists on the MOR, presenting a theoreti cally attractive means of relapse prevention in detoxified pa tients with OUD. 7 However, the oral formulation of NTX is characterized by poor compliance. 8 To overcome this obstacle, a onceamonth, injectable, extendedrelease naltrexone (XR NTX) was approved by the US Food and Drug Administration in 2010. 9, 10 Despite its demonstrated clinical effectiveness and broad insurance coverage, XRNTX use in the United States has been limited. 11 Motivational and neural mechanisms un derlying XRNTX action may be one of the factors responsible for the gap between effectiveness and acceptance. These mech anisms are not well understood, although their importance in the overall effectiveness of an addiction treatment is well rec ognized. 12 For example, it is still unknown how XRNTX modu lates the neurocognitive processing of drugrelated stimu li in patients with OUD, whether the effect of XRNTX on neural activity is associated with negative motivational states (e.g., withdrawal), 13 and how long the neurocognitive XRNTX effects endure after the treatment is discontinued. 14 After repeatedly signalling drug arrival, drugrelated visual and olfactory stimuli can become conditional stimuli or "cues" that elicit conditioned responses. 15 Such responses include ap petitive drug motivation (craving) and, especially in patients with OUD, conditioned withdrawallike symptoms. [16] [17] [18] These cuetriggered responses are thought to play an important role in perpetuating drug use and relapse. 16, 17, 19 Drug cues have been shown to activate the dopaminergic mesocorticolimbic (MCL) pathway that includes the VTA, NAcc and medial orbi tofrontal cortex (mOFC). 20, 21 Therefore, MCL drug cue reactiv ity has the potential to serve as a biomarker of addiction. 12, 18, 22 Extendedrelease naltrexone has been shown to modulate both neurophysiological and behavioural responses to drug cues in heroinaddicted individuals, including decreased cue reactiv ity in the caudate and medial prefrontal cortex, and reduction in craving. 12, 23 In addition, XRNTX also decreases responses to appetitive natural stimuli, such as sweet taste 24 and palatable food, 25 while tending to increase aversive responses. 25 How ever, prior studies have not directly compared the effects of XRNTX on the neural and behavioural responses to drug related stimuli versus nondrug appetitive and aversive stimu li. Such a comparison would help determine to what ex tent XRNTX related modulation differs between drugrelated and nondrug stimuli. This is crucial if neural responses to drug stimuli are to be used for clinical treatment monitoring.
Opioid addiction has been conceptualized as a progression from impulsive seeking of reward to compulsive avoidance of withdrawal and is characterized by a high rate of relapse after abstinence is achieved. 26 Withdrawal symptoms play a central role in the maintenance of ongoing drug use in patients with OUD, 13, 27 either directly or by increasing the positive reinfor cing effects of opioids. Increasing the positive reinforcing ef fects in turn drives future drugseeking behaviour when the patient is again in withdrawal. 27 Withdrawalbased motivation may coexist with motivation related to the powerful positive reinforcement effects mediated by the MOR. 3 The positive re inforcing effects are especially important for the initiation of drug use and cuetriggered relapse after pharmacologic with drawal has ceased. At the neuropharmacological level, with drawal induces a reduction in the extracellular tonic dopamine concentration in the MCL that elevates the sensitivity to phasic dopamine release. This results in a heightened MCL reactivity to both the drug and drug related cues. 28 The present study aimed to test the differential effect of XR NTX on the MCL response to opioidrelated versus non opioid evocative visual stimuli in detoxified individuals with OUD. We hypothesized that XRNTX reduces the brain response to opioidrelated but not sexual or aversive stimuli in patients with OUD, and that this effect is associated with the concur rent changes in the severity of withdrawal symptoms. To test this hypothesis, we studied the brain response to visual stimu li in patients with OUD before, during and after XR NTX treatment using functional MRI (fMRI) and a cue reactivity paradigm comprising drug, sexual and aversive stimuli. Given the positive incentive value of drugrelated stimuli 27 and the repeated recruitment of the MCL reward cir cuit (e.g., NAcc and mOFC) in processing rewarding stimu li, [29] [30] [31] we focused on these regions. We examined whether XRNTX differentially modulates their neural responses to opioid related versus opioidunrelated stimuli and whether such modulation is associated with opioid withdrawal.
Methods

Participants
We recruited participants through newspaper advertisements in Philadelphia, Pa., between 2012 and 2014. Benefits of partici pation included free, medically supervised, 3month treatment for OUD, referral to community providers after study comple tion, and compensation for the time and travel expenses related to participation. All participants gave written informed consent to participate in the protocol, which was approved by the Uni versity of Pennsylvania Institutional Review Board.
Inclusion and exclusion criteria
The DSMIVTR diagnosis of opioid dependence was estab lished using the bestestimate format based on all available sources of information, including history, the Structured Clinical Interview for DSMIV 32 and the Addiction Severity Index 5th Edition. 33 Inclusion criteria were age between 18 and 59 years; a DSMIVTR diagnosis of opioid dependence confirmed by selfreport and medical records documenting daily opioid use for more than 2 weeks in the past 3 months; evidence of detoxification from opioids before XRNTX injections, estab lished by urine drug screen (Redwood Toxicology Labora tory) and a negative naloxone challenge test; and good phys ical health ascertained by history and physical examination, blood chemistry and urinalysis.
Exclusion criteria were current use of medications that could confound blood oxygen level-dependent fMRI re sponse, such as antidopaminergic agents, anticonvulsants, and βblockers; current psychosis, dementia, intellectual dis ability, or lifetime history of schizophrenia; clinically signifi cant cardiovascular, hematologic, hepatic, renal, pulmonary, metabolic, gastrointestinal, neurologic, or endocrine abnor malities; pregnancy or breastfeeding; history of clinically sig nificant head trauma; contraindications for XRNTX treat ment, including medical conditions requiring opioid analgesics such as chronic pain disorder, planned surgery, obesity, elevated liver enzymes more than 3 times the upper limit of normal, or failure to complete opioid detoxification; contraindications for MRI, such as indwelling magnetically active foreign bodies, or fear of enclosed spaces; and current use of illicit drugs (e.g., cocaine) except marijuana.
Functional MRI task
During the fMRI sessions, participants viewed 4 categories of visual stimuli (cues) in a pseudorandom order: drug, sexual, aversive and neutral. Each stimulus category included 24 unique images that were presented twice, resulting in a J Psychiatry Neurosci 2018;43(4) total of 192 trials (see Appendix 1, available at jpn.ca/170036a1, "Stimuli" section, for more details).
Each trial of the fMRI cuereactivity task consisted of a stimulus displayed for 500 ms followed by a crosshair dis played for 1500 ms. The stimulus trials were interspersed with 48 baseline periods during which crosshairs were dis played for 2000 ms. Pseudorandom order of the stimuli trials and baseline periods was generated using optseq2 (https:// surfer.nmr.mgh.harvard.edu/optseq). The task duration was 8 minutes, 28 seconds.
Behavioural assessments
Before the fMRI cuereactivity task, physical symptoms of opi oid withdrawal were measured using the Clinical Opiate Withdrawal Scale (COWS), 34 which is a clinician administered scale that assesses 11 common opioid withdrawal symptoms. After COWS assessment, selfreported opioid craving and withdrawal were recorded using a 10point scale (0 = none; 9 = extremely). Following the cue reactivity task, the selfreported opioid craving and withdrawal and the COWS assessments were repeated (see Appendix 1, "Additional behavioural as sessments" section, for more details).
Procedure
After providing informed consent, participants completed baseline assessments and were offered up to 3 monthly intra muscular injections of XRNTX (380 mg gradually released from dissolvable polymer microspheres over a period of 1 month; manufactured by Alkermes Inc., under the brand name Vivitrol; see Appendix 1, "Study medication" section, for more details).
About 3 days (mean 3.13 ± 8.35, range 0-36 d) before the first XRNTX injection, participants underwent the first fMRI session (i.e., the pretreatment session). The second fMRI ses sion (i.e., the ontreatment session) was completed 10.17 ± 2.44 (range 7-14) days after the first XRNTX injection. A third optional posttreatment fMRI session was completed 41.64 ± 9.98 (range 28-64) days after the last XRNTX injec tion; however, the posttreatment session was not the main fo cus of the present study. The methods and results pertaining to the posttreatment session are included in Appendix 1 ("Procedure and analyses of the posttreatment session" and "Results from the posttreatment session" sections). During each fMRI session, the COWS, selfreported craving and self reported withdrawal were assessed before the fMRI cue reactivity task and immediately after the task.
Behavioural data analysis
Because of the high participant attrition rate, the present analy ses focused primarily on the pre and ontreatment sessions. We analyzed participants' COWS and selfreported craving and withdrawal scores using 2way repeated measures analy sis of variance (ANOVA), which tested the main effect of cue exposure (pre v. postfMRI), the main effect of session (pre v. ontreatment) and their interaction. Exploratory analyses in volving the optional posttreatment fMRI session are reported in Appendix 1 ("Procedure and analyses of the posttreatment session" section).
MRI data acquisition and analysis
We acquired the MRI data using a Siemens Tim Trio 3 T sys tem and analyzed the data using SPM 8 (Wellcome Trust Centre for Neuroimaging). Images were preprocessed and subjected to individuallevel statistical analyses by modelling the effects of drug, sexual and aversive stimuli compared with the neutral stimuli. At the group level, the bilateral NAcc and mOFC were defined as regions of interest (ROIs) based on their consistent involvement in the processing of positive incentive value in general [29] [30] [31] and in response to drug cues in particular. 20 For each ROI, the contrast values for drug, sexual and aversive stimuli during the pre and on treatment sessions were subjected to 2 × 3 repeatedmeasures ANOVAs with session (pre v. ontreatment) and stimulus (drug v. sexual v. aversive) as withinsubjects variables. We explored the session × stimulus interaction in other brain re gions by conducting wholebrain ANOVA. Significant activa tion was identified at a corrected p < 0.05 threshold (voxel level p < 0.005, cluster extent > 137 voxels). See Appendix 1, "MRI data acquisition" and "MRI data analyses" sections, for more details.
We tested the Pearson correlation between the reduction in drugrelated neural activity and the reduction in opioid craving and withdrawal due to the XRNTX treatment (i.e., pre minus ontreatment). PrefMRI opioid craving and with drawal measures were used for correlation analyses so that they were not influenced by exposure to drug cues.
Results
Participants
Twentyfive individuals with OUD were enrolled in the study. One participant was excluded because of concurrent use of cocaine, leaving 24 participants (15 men, 9 women, mean age 30.21 ± 8.47 [range yr) for the final analysis. Twentyone participants were righthanded, and three were lefthanded. Mean education level was 13.88 ± 2.42 (range 19-24) years. Four participants used heroin exclusively, 7 used prescription opioids exclusively, and 13 used both with expressed preference for one or the other drug category.
Participant attrition and missing data
All 24 participants received the first XRNTX injection, 17 (70.83%) received both the first and second XRNTX injections, and 15 (62.50%) received all 3 injections. All 24 participants completed the pre and ontreatment fMRI sessions. Four par ticipants were missing 1 or more COWS scores. Eleven (45.83%) completed the posttreatment COWS and selfreported craving and withdrawal assessments. Nine (37.50%) completed the posttreatment fMRI session. See Appendix 1, "Participant attri tion and missing data" section, for more details.
Behavioural results
There were main effects of session on opioid withdrawal symp toms as measured by COWS (F 1,19 = 6.40, p = 0.020), on self reported craving (F 1,23 = 34.64, p < 0.001) and on self reported withdrawal (F 1,23 = 9.74, p = 0.005), such that the COWS scores, selfreported craving and selfreported withdrawal significantly declined from the pretreatment to the ontreatment sessions. We also observed a significant main effect of cue exposure on craving (F 1,23 = 7.38, p = 0.012), such that the fMRI cuereactivity task increased participants' craving for opioids. Cue exposure did not have a main effect on the COWS scores ( Table 1 ).
Exploratory analyses of 11 participants showed that both the COWS scores and the selfreported craving and withdrawal at the posttreatment session were lower than at the pretreatment session. These scores were either lower than, or comparable to those at the ontreatment session (see Appendix 1, "Results from the posttreatment session" section, for more details).
Functional MRI results
Significant session × stimulus interaction was observed in the NAcc (F 2,46 = 5.29, p = 0.009; Fig. 1A ) and the mOFC (F 2,46 = 5.47, p = 0.007; Fig. 1B ). Post hoc analysis showed that the neural response to drug cues in these regions during the pretreatment session was greater than during the on treatment session (NAcc: 0.72 ± 2.17 v. -1.62 ± 3.54, t 23 = 2.62, p = 0.015; mOFC: 0.94 ± 3.11 v. 1.58 ± 4.34, t 23 = 2.31, p = 0.030). The neural response to sexual or aversive cues did not differ between the pre and ontreatment sessions (NAcc, sexual: t 23 = 1.12, p = 0.27; NAcc, aversive: t 23 = -1.09, p = 0.29; mOFC, sexual: t 23 = 0.13, p = 0.90; mOFC, aversive: t 23 = -0.45, p = 0.66). We also performed pairwise comparisons of the change in neural response to different stimuli. The change scores were calculated as pretreatment minus ontreatment. We found that the reduction in NAcc response to drug stimu li (mean 2.34 ± 4.38) did not significantly differ from that to sexual stimuli (1.39 ± 6.05, t 23 = 0.99, p = 0.33), but was significantly greater than that to aversive stimuli (-0.93 ± 4.14, t 23 = 3.06, p = 0.006). The reduction in NAcc response to sexual stimuli was significantly greater than that to aversive stimuli (t 23 = 2.17, p = 0.041). We also found that the reduc tion in mOFC response to drug stimuli (2.52 ± 5.35) was greater than that to sexual stimuli (0.16 ± 6.00, t 23 = 2.45, p = 0.022) and that to aversive stimuli (-0.45 ± 4.86, t 23 = 3.42, p = 0.002). The change in mOFC response to sexual and aversive stimuli did not significantly differ (t 23 = 0.60, p = 0.55).
We conducted a wholebrain analysis to explore the effect of session × stimulus interaction on the neural activity in other brain regions. We found that the interaction was asso ciated with a single cluster in the ventral striatum that ex tended to the mOFC (k = 679, Z = 3.45, Montreal Neurologic al Institute [MNI] coordinates: x, y, z = 4, 18, -2; Fig. 1C ).
Exploratory analyses of the 9 participants with available posttreatment data showed that the NAcc response to drug stimuli at the posttreatment session was comparable to that at the pretreatment session and greater than that at the on treatment session. A similar trend was observed for the mOFC (see Appendix 1, "Results from the posttreatment session" section, for more details).
Correlation analysis
The reduction in drugrelated neural activity between the pre and ontreatment sessions in the NAcc was significantly correlated with the decline in withdrawal symptoms indexed by the COWS score (r = 0.58, p = 0.005; Fig. 2A ). Reduced re sponse to drug cues in the mOFC and the decline in COWS scores were not significantly correlated (r = 0.32, p = 0.15). Conversely, the decline in selfreported subjective with drawal symptom severity was significantly correlated with the reduction in drugrelated neural activity in the mOFC (r = 0.55, p = 0.005; Fig. 2B ), but not in the NAcc (r = 0.25, p = 0.25). No correlation was found between selfreported craving and NAcc response (r = -0.12, p = 0.57) or between craving and mOFC response (r = 0.08, p = 0.70).
Discussion
Using fMRI, we compared the effects of XRNTX on the brain response to drugrelated, sexual and aversive visual stimuli in detoxified patients with OUD. We found that the NAcc and mOFC brain responses to opioidrelated cues were sig nificantly reduced after 2 weeks of XRNTX treatment, whereas their responses to nondrug stimuli did not signifi cantly change. Moreover, the reduction in NAcc response was positively correlated with a decline in the objectively measured symptoms of opioid withdrawal, whereas the re duction in mOFC response was positively correlated with a decline in selfreported severity of withdrawal. The NAcc and mOFC are the key components of the MCL approach and reward system. Our findings suggest a differential effect of XRNTX on the MCL responses to opioidrelated and nor mally evocative stimuli in abstinent patients with OUD. In addition, the individual difference in the decline of opioid withdrawal was associated with XRNTX's blunting of MCL cue reactivity. 
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The MCL system plays an important role in the processing of pathologically rewarding stimuli across a range of addic tive substances and behaviours, such as alcohol, 35 mari juana, 36 cocaine, 37 opioids 12,18,23 and gambling. 38 Metaanalyses have shown that the NAcc and the mOFC are among the core MCL regions engaged in drug cue reactivity. 20 Consistent with this literature, our data show heightened NAcc and mOFC responses to drugrelated visual cues in heroin and prescription opioid abusers before XRNTX treatment. Drug cue reactivity has been a candidate biomarker and therapeu tic target 22 because of its important role in triggering relapse. Extendedrelease naltrexone is an effective treatment of OUD that significantly improves treatment retention, reduces re lapse and reduces subjective reports of craving. 39 Recent studies have also found that XRNTX reduces the brain re sponse to visual heroin cues among heroindependent pa tients. 12, 21 The present study extends previous findings by showing that the effect of XRNTX on the NAcc and mOFC responses to opioidrelated cues is selective. The fact that XR NTX has little effect on the MCL responses to naturally evoc ative stimuli regardless of valence (i.e., sexual and aversive pictures) provides neurobiological evidence in support of prior observational studies showing no change in pleasurable activities during treatment. 40 These findings also raise the possibility that in patients with OUD, opioidrelated but not naturally evocative visual stimuli induce opioid neurotrans mission that has been blunted by XRNTX.
An exploratory wholebrain analysis revealed that no re gions showed a significant interaction other than our a priori MCL ROIs. This finding is unlikely to be a false negative since we used a wholebrain threshold similar to the one that has been shown to produce balanced type I and type II er rors. 41 Whether or not this threshold produces an excessive type I error rate remains a subject of continued discus sion. [42] [43] [44] [45] This finding confirms that the NAcc and mOFC are the only regions that change their sensitivity to drug cues in response to XRNTX. A similar fMRI study that examined the cue reactivity in a group of methadone maintenance patients with OUD showed that a regular daily dose of methadone re duced the MCL neural response to opioid cues in the amyg dala and insula, but not in the NAcc and mOFC. 18 Therefore, while both opioid agonist and antagonist treatments have been proven to be effective for OUD, their effectiveness may be achieved by acting on different subcircuits of the MCL system. It would be interesting for future studies to test whether and how the distinct patterns of reduction in MCL cue reactivity account for the fundamental motivational dif ferences between agonist and antagonist treatments.
The reduction in the MCL response to drug cues induced by XRNTX was correlated with a decline in withdrawal symptom severity. The correlation suggests that XRNTX has a greater impact on the cuetriggered MCL activation in indi viduals with lower levels of ongoing withdrawal. One possi ble explanation could be that these individuals had greater recovery of endogenous opioid function, making them more responsive to the effects of naltrexone. 46 Moreover, given the role of the MCL system in negative reinforcement, 47 it is also possible that these individuals were less susceptible to the negative reinforcing effects of drug cues during XRNTX treatment. Specifically, the reduction in the NAcc and mOFC cue reactivity was associated with a decline in objective and selfreport basal withdrawal symptomatology, respectively. This association requires further study to determine whether withdrawal symptoms have a predictive value for XRNTX outcomes, such as adherence 23 and relapse, as well as whether withdrawal symptoms causally influence these out comes. The distinct correlation patterns of NAcc and mOFC with cliniciandetermined and selfreported withdrawal symptoms, respectively, is consistent with the notion that compared with the NAcc, the mOFC is more responsive to subjective rewardrelated experience. 30 In addition, we found that whereas selfreported opioid craving decreased from pre to ontreatment sessions, such a decrease was not associ ated with the XRNTX effect on MCL cue reactivity. The lack of correlation with craving does not preclude the possibility that XRNTX reduces the positive reinforcing effects of opi oids. 27, 48 Rather, it may reflect the fact that craving is more difficult to report (undermining correlations) than with drawal symptoms, or that craving has a closer association with brain regions outside the examined ROIs (e.g., the an terior cingulate cortex and the temporal lobe 49 ). We found that XRNTX had little effect on the brain re sponse to the normally evocative aversive and appetitive stimuli categories. This observation extends the findings of prior studies in alcoholdependent patients that reported a reduction in the brain response in several cortical areas spe cific to alcoholrelated cues 50 but did not find reduced plea surable activities during XRNTX treatment. 40 Nonetheless, the literature on the effect of opioid antagonism on the neural and behavioural responses to normally evocative stimuli re mains mixed. For example, acute administration of naltrex one reduces sexual behaviour in previously sexually active male monkeys 51 and diminishes lambs' preference for their own mothers (compared with an unknown ewe). 52 In healthy humans, naltrexone attenuated the positive feelings associ ated with social connection, 53 increased brain response (in the amygdala and insula) to aversive stimuli, 25 and reduced brain response (in the caudate and the anterior cingulate cor tex) to appetitive food stimuli. 25 In individuals with opioid addiction, XRNTX treatment was associated with a decline in their liking of the sweet taste 24 and their perception of cute ness of baby portraits. 54 The divergence between these re ports and our findings could stem from several factors. First, there are significant methodological differences, including the much higher naltrexone plasma levels achieved by acute doses of oral naltrexone in contrast with an extendedrelease preparation such as XRNTX. Second, none of the studies was performed in patients with OUD receiving XRNTX. In the study methodologically closest to ours, 25 the brain regions showing decreased response to normally appetitive stimuli did not overlap with the brain regions that showed session × stimulus interactions in our study. Finally, if XRNTX effects on naturally evocative stimuli are subtle relative to its effects on drugrelated stimuli, it is possible that our sample size was insufficient to detect them. Future work is needed to ad dress these possibilities.
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Limitations
Our results should be interpreted with a number of caveats. First, the small size of prescription opioids versus heroin subgroups did not allow us to directly compare them. Such a comparison would be important to conduct in future studies, given the growing prevalence of prescription opi oid abuse. 55, 56 Second, the study was not placebocontrolled. Such a control condition would be challenging in the con text of XRNTX treatment. Participants almost invariably test the opioid blockade in the early stages of treatment 57 and are able to quickly discover whether they are in the XRNTX or placebo group. Moreover, testing opioid block ade by a patient on placebo who may try a higher than usual dose to achieve desired effects could increase the risk of opioid overdose. Third, our stimuli were not matched on pleasantness (see Appendix 1, "Stimuli" sec tion, for more details) and were not assessed on other dimensions, including arousal, dominance, 58 or effort ex penditure to view. 59 Finally, the limited number of brain regions of interest (i.e., NAcc and mOFC), the focus on the session × stimulus interaction instead of pairwise compari son between sessions across stimulus categories, and a rel atively small sample size may have limited our ability to fully unravel the effects of XRNTX on brain function (e.g., neural responses to sexual and aversive stimuli). It is our hope that our study sets the stage for filling these gaps in future research.
Conclusion
Extendedrelease naltrexone reduces the NAcc and mOFC response to opioid related visual stimuli in detoxified pa tients with OUD. This effect is specific to opioidrelated stimuli in the mOFC but not in the NAcc. The reduction in the MCL response to opioidrelated cues is associated with reduction in opioid withdrawal, but not with craving symp tomatology. Together, these findings support the potential for clinical application of drug cuereactivity paradigms paired with neuroimaging to monitor XRNTX treatment.
